Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, James Buteau, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Yan Zhang, Martin R. Stockler, Scott Williams, Andrew Martin, Ian D. Davis, Tim Akhurst, Ramin Alipour, Dale L. Bailey, Patricia Banks, Alexis Beaulieu, Louise Campbell, Megan Crumbaker, Nattakorn Dhiantravan, Anis Hamid, Mohammad B. Haskali, Terry Hung, Grace Kong, Nick Lawrence, Jeremy Lewin, Michael McCarthy, Kate Moodie, Declan G. Murphy, Andrew Nguyen, David Pook, Aravind Ravi Kumar, Paul Roach, Peter Roselt, Javad Saghebi, Geoffrey Schembri, Lavinia Spain, Shalini Subramaniam, Sue Ping Thang, Paul Thomas, Ben Tran, Roslyn E. Wallace, Sonia Yip (2023). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. , 25(1), DOI: https://doi.org/10.1016/s1470-2045(23)00529-6.